Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -4.24%8.66M | -35.83%17.14M | -58.86%9.05M | -69.10%3.11M | 71.98%26.72M | 1,610.54%31.37M | 563.08%21.99M | 236.16%10.05M | -15.65%15.54M | -114.63%-2.08M |
| Operating income | -4.24%8.66M | -35.83%17.14M | -58.86%9.05M | -69.10%3.11M | 71.98%26.72M | 1,610.54%31.37M | 563.08%21.99M | 236.16%10.05M | -15.65%15.54M | -114.63%-2.08M |
| Cost of sales | -3.42%-5.66M | 25.24%-10.72M | 56.55%-5.47M | 72.01%-1.63M | -49.65%-14.33M | -855.26%-18.03M | -403.67%-12.58M | -207.47%-5.81M | 36.57%-9.58M | 119.90%2.39M |
| Operating expenses | -3.42%-5.66M | 25.24%-10.72M | 56.55%-5.47M | 72.01%-1.63M | -49.65%-14.33M | -855.26%-18.03M | -403.67%-12.58M | -207.47%-5.81M | 36.57%-9.58M | 119.90%2.39M |
| Gross profit | -15.96%3.01M | -48.09%6.43M | -61.95%3.58M | -65.13%1.48M | 107.89%12.38M | 4,205.16%13.35M | 1,656.79%9.4M | 314.56%4.24M | 79.59%5.96M | -85.93%310K |
| Selling expenses | 32.00%-102K | 31.95%-477K | 60.42%-150K | 67.57%-72K | -43.06%-701K | -79.82%-597K | -65.50%-379K | -22.65%-222K | -38.81%-490K | -55.87%-332K |
| Administrative expenses | 1.81%-7.2M | -22.71%-29.21M | 12.26%-7.33M | 1.54%-3.97M | -0.45%-23.8M | -28.24%-12.56M | -32.35%-8.35M | -16.58%-4.03M | -35.95%-23.7M | 19.28%-9.79M |
| Impairment and provision | ---- | -551.87%-10.28M | ---- | ---- | 229.85%2.28M | ---- | ---- | ---- | 88.56%-1.75M | ---- |
| -Other impairment is provision | ---- | -551.87%-10.28M | ---- | ---- | 229.85%2.28M | ---- | ---- | ---- | 82.66%-1.75M | ---- |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | 18.23%-5.1M | ---- | ---- | ---- | 5.46%-6.24M |
| Special items of operating profit | -0.81%1.22M | 17.64%9.88M | -78.33%1.23M | 10.58%627K | -76.32%8.4M | 249.33%6.25M | 378.53%5.66M | 1.07%567K | 1,663.04%35.48M | -21.11%1.79M |
| Operating profit | -14.95%-3.08M | -1,539.15%-23.65M | -142.25%-2.68M | -445.80%-1.93M | -109.31%-1.44M | 109.41%1.34M | 206.19%6.33M | 107.85%559K | 148.36%15.5M | 1.44%-14.26M |
| Financing cost | 15.98%-1.04M | -11.59%-9.97M | 59.00%-1.23M | -140.19%-2.07M | -7.71%-8.93M | ---- | 27.82%-3.01M | ---861K | 1.34%-8.29M | ---- |
| Earning before tax | -5.19%-4.11M | -224.05%-33.62M | -217.57%-3.91M | -1,224.83%-4M | -243.96%-10.38M | 109.41%1.34M | 132.82%3.32M | 95.76%-302K | 117.81%7.21M | 1.44%-14.26M |
| After-tax profit from continuing operations | -5.19%-4.11M | -224.05%-33.62M | -217.57%-3.91M | -1,224.83%-4M | -243.96%-10.38M | 109.41%1.34M | 132.82%3.32M | 95.76%-302K | 117.81%7.21M | 1.44%-14.26M |
| Earning after tax | -5.19%-4.11M | -224.05%-33.62M | -217.57%-3.91M | -1,224.83%-4M | -243.96%-10.38M | 109.41%1.34M | 132.82%3.32M | 95.76%-302K | 117.81%7.21M | 1.44%-14.26M |
| Minority profit | ---- | -605.88%-86K | ---- | ---- | 241.67%17K | ---- | ---- | ---- | 82.09%-12K | ---- |
| Profit attributable to shareholders | -5.19%-4.11M | -222.69%-33.53M | -217.57%-3.91M | -1,224.83%-4M | -243.95%-10.39M | 109.41%1.34M | 132.82%3.32M | 95.76%-302K | 117.87%7.22M | 1.44%-14.26M |
| Basic earnings per share | 0.00%-0.013 | -266.67%-0.11 | -218.18%-0.013 | -1,200.00%-0.013 | -250.00%-0.03 | 108.70%0.004 | 133.33%0.011 | 95.65%-0.001 | 115.27%0.02 | 2.13%-0.046 |
| Diluted earnings per share | 0.00%-0.013 | -266.67%-0.11 | -218.18%-0.013 | -1,200.00%-0.013 | -250.00%-0.03 | 108.70%0.004 | 133.33%0.011 | 95.65%-0.001 | 0.02 | 2.13%-0.046 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.